Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor

Korean J Intern Med. 2018 Mar;33(2):432-434. doi: 10.3904/kjim.2015.295. Epub 2016 Jul 7.

Authors

Eunjung Yim¹, Ho Jung An¹, Uiju Cho², Youngwoo Kim¹, Seung Hoon Kim¹, Yeon-Geun Choi¹, Byoung Yong Shim¹

Affiliations

¹ Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
² Department of Pathology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.

No abstract available

Keywords: Gastrointestinal stromal tumors; Imatinib mesylate; KIT mutation.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents
Benzamides
Drug Resistance, Neoplasm*
Gastrointestinal Stromal Tumors* / drug therapy
Gastrointestinal Stromal Tumors* / genetics
Humans
Imatinib Mesylate* / pharmacology
Male
Mutation
Piperazines
Proto-Oncogene Proteins c-kit* / genetics
Pyrimidines

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Proto-Oncogene Proteins c-kit